Tumor volume and percent positive lymph nodes as a predictor of 5-year survival in colorectal cancer
Authors:
- Lisa S. PoritzLPLisa S. Poritz
- Rishabh SehgalRSRishabh Sehgal
- Kimberly HartnettKHKimberly Hartnett
- Arthur BergABArthur Berg
- Walter A. KoltunWKWalter A. Koltun
- 1 October 2011
- Vol. 150 (4) , 649-655
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Cancer Statistics, 2010CA: A Cancer Journal for Clinicians, 2010
- Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon CancerJournal of Clinical Oncology, 2009
- Prognosis of Patients With Colorectal Cancer Is Associated With Lymph Node RatioAnnals of Surgery, 2008
- Lymph Node Ratio: Role in the Staging of Node-Positive Colon CancerAnnals of Surgical Oncology, 2008
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006
- Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph NodesJournal of Clinical Oncology, 2005
- Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition StagingJNCI: Journal of the National Cancer Institute, 2004
- Role of the Extended Lymphadenectomy in Gastric Cancer Surgery: Experience in a Single InstitutionAnnals of Surgical Oncology, 2003
- Outcome of ratio of lymph node metastasis in gastric carcinomaAnnals of Surgical Oncology, 2002
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyThe Lancet, 2002